Your browser doesn't support javascript.
loading
Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M; Khoury, Thaer; Zirpoli, Gary R; Bshara, Wiam; Davis, Warren; Omilian, Angela; Nair, Priya; Ondracek, Rochelle P; Cheng, Ting-Yuan David; Miller, C Ryan; Hwang, Helena; Thorne, Leigh B; O'Connor, Siobhan; Bethea, Traci N; Bell, Mary E; Hu, Zhiyuan; Li, Yan; Kirk, Erin L; Sun, Xuezheng; Ruiz-Narvaez, Edward A; Perou, Charles M; Palmer, Julie R; Olshan, Andrew F; Ambrosone, Christine B; Troester, Melissa A.
Afiliação
  • Allott EH; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Geradts J; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Cohen SM; Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Khoury T; Harvard Medical School, Boston, MA, USA.
  • Zirpoli GR; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bshara W; Translational Pathology Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Davis W; Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Omilian A; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Nair P; Massachusetts General Hospital, Boston, MA, USA.
  • Ondracek RP; Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Cheng TD; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Miller CR; Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Hwang H; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Thorne LB; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • O'Connor S; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Bethea TN; Department of Epidemiology, University of Florida, Gainesville, FL, USA.
  • Bell ME; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hu Z; Translational Pathology Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Li Y; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Kirk EL; Department of Pathology, University of Texas Southwestern, Dallas, TX, USA.
  • Sun X; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ruiz-Narvaez EA; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Perou CM; Slone Epidemiology Center at Boston University, Boston, MA, USA.
  • Palmer JR; Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
  • Olshan AF; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ambrosone CB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Troester MA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Breast Cancer Res ; 20(1): 12, 2018 02 06.
Article em En | MEDLINE | ID: mdl-29409530
ABSTRACT

BACKGROUND:

Breast cancer subtype can be classified using standard clinical markers (estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)), supplemented with additional markers. However, automated biomarker scoring and classification schemes have not been standardized. The aim of this study was to optimize tumor classification using automated methods in order to describe subtype frequency in the African American Breast Cancer Epidemiology and Risk (AMBER) consortium.

METHODS:

Using immunohistochemistry (IHC), we quantified the expression of ER, PR, HER2, the proliferation marker Ki67, and two basal-like biomarkers, epidermal growth factor receptor (EGFR) and cytokeratin (CK)5/6, in 1381 invasive breast tumors from African American women. RNA-based (prediction analysis of microarray 50 (PAM50)) subtype, available for 574 (42%) cases, was used to optimize classification. Subtype frequency was calculated, and associations between subtype and tumor characteristics were estimated using logistic regression.

RESULTS:

Relative to ER, PR and HER2 from medical records, central IHC staining and the addition of Ki67 or combined tumor grade improved accuracy for classifying PAM50-based luminal subtypes. Few triple negative cases (< 2%) lacked EGFR and CK5/6 expression, thereby providing little improvement in accuracy for identifying basal-like tumors. Relative to luminal A subtype, all other subtypes had higher combined grade and were larger, and ER-/HER2+ tumors were more often lymph node positive and late stage tumors. The frequency of basal-like tumors was 31%, exceeded only slightly by luminal A tumors (37%).

CONCLUSIONS:

Our findings indicate that automated IHC-based classification produces tumor subtype frequencies approximating those from PAM50-based classification and highlight high frequency of basal-like and low frequency of luminal A breast cancer in a large study of African American women.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article